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Abstract
Background: Our aim is to identify the relation of leptin, adiponectin and insulin resistance to bone mineral density (BMD) in type 2 
diabetic postmenopausal women and compare it with that experienced by nondiabetics.
Material and methods: Seventy six postmenopausal female patients were included in the study. Postmenopausal type 2 diabetic (n = 19) 
and nondiabetic patients (n = 19) with spine and/or hip BMD T score lower than -2 were included in the study, and postmenopausal type 2 
diabetic (n = 20) and nondiabetic women (n = 18) with normal BMD (T score > –1) were selected as control groups. Those receiving therapy 
for osteoporosis, over the age of 65, those who had a disease and were taking a medication that could affect bone metabolism were excluded. 
Biochemical tests, as well as leptin, adiponectin and insulin levels, were measured and insulin resistance was calculated using the HOMA test. 
Results: There was no correlation between low BMD and leptin, adiponectin and insulin resistance. There was only a negative correlation 
between leptin and femur Ward’s triangle BMD. 
Conclusion: Further large-scale studies must to be performed in order to analyse the effects of leptin, adiponectin and insulin resistance 
on bone metabolism in type 2 diabetic patients. (Pol J Endocrinol 2011; 62 (5): 429–435)
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Streszczenie
Wstęp: Celem badania było porównanie zależności między stężeniami leptyny i adiponektyny oraz insulinoopornością a gęstością 
mineralną kości (BMD) u kobiet po menopauzie chorujących na cukrzycę typu 2 i u osób z niechorującej na cukrzycę grupy kontrolnej.
Materiał i metody: Do badania zrekrutowano łącznie 76 kobiet po menopauzie, które podzielono na grupy obejmujące kobiety chorujące 
na cukrzycę typu 2 (n = 19) i bez cukrzycy (n = 19), u których wartość T score dla BMD kręgosłupa i/lub bliższego odcinka kości udowej 
wynosiło mniej niż -2 oraz chore na cukrzycę typu 2 (n = 20) i niechorujące na cukrzycę (n = 18) z prawidłowymi wartościami BMD 
(T score > -1). Kryteria wykluczenia obejmowały stosowanie leków przeciwosteoporotycznych, wiek ponad 65 lat, choroby lub terapie 
mogące wpływać na metabolizm kostny. U uczestniczek badania wykonano badania biochemiczne, oznaczono stężenia leptyny, adipo-
nektyny i insuliny oraz oszacowano stopień insulinooporności HOMA.
Wyniki: Nie zaobserwowano korelacji między niskimi wartościami BMD a stężeniami leptyny i adiponektyny oraz insulinoopornością. 
Stwierdzono jedynie odwrotną zależność między stężeniem leptyny a BMD kości udowej w obrębie trójkąta Warda.
Wnioski: Konieczne są dalsze badania obejmujące dużą grupę chorych, aby ustalić wpływ stężeń leptyny i adiponektyny oraz insulino-
oporności na metabolizm kostny u chorych na cukrzycę typu 2. (Endokrynol Pol 2011; 62 (5): 429–435)
Słowa kluczowe: leptyna, adiponektyna, insulinooporność, gęstoścć mineralna kości
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Osteoporosis is a systemic disease of the skeleton 
characterised by low bone mass and disruption of the 
microarchitecture of the bone tissue, which is followed 
by an increase in bone fragility and a tendency to frac-
ture [1]. Since bone mineral density (BMD) increases, 
and the fracture risk decreases, in obese people, it has 
been argued that there is a positive relation between 
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associated with increased weight elevate BMD. Increased 
aromatisation of androgens into oestrogen in the fat tis-
sues, and high free sex steroid levels which are associated 
with a decrease of sex hormone binding globulin in obese 
people also increase bone mass [4]. Similarly in the obese, 
hyperinsulinaemia due to insulin resistance shows a di-
rect mitogenic effect and increases bone formation [4]. 
Bone is a continuously regenerated tissue. The 
bone remodelling unit is composed of osteoclasts for 
bone resorption, and osteoblasts for bone formation. 
Osteoclasts are composed of haematopoietic precur-
sors in circulation and in bone marrow. Osteoblasts 
and adipocytes derive from mesenchymal stem cells 
[5, 6]. Hormones such as leptin and adiponectin, and 
proinflammatory cytokines such as tumour necrosis fac-
tor and interleukin-6 may also affect bone remodelling.
The relationship between leptin and BMD has been 
much debated. There are studies in the literature report-
ing a positive correlation between leptin and BMD [7–9], 
others reporting no significant relation [10–13], and yet 
others reporting a negative correlation [4, 14]. Blain et 
al. [7] reported a significant positive correlation between 
the full body, femur neck and lumbar vertebrae BMD, 
and serum leptin levels and suggested that leptin was 
an important predictor of BMD in postmenopausal 
women. Goulding et al. [8] and Yamauchi et al. [9] 
found similar results. The above mentioned studies 
point out the positive correlation between leptin and 
bone metabolism. This situation can be explained by 
the direct stimulatory effect of leptin on osteoblast dif-
ferentiation, which is one of the effects of leptin on bone 
metabolism [6]. There are also some other studies which 
demonstrate that locally secreted leptin from adipocytes 
in the bone marrow increases bone formation [15]. This 
fact suggests local production of leptin could have a role 
in bone metabolism [12]. 
The relationship between diabetes and BMD has 
been investigated in many studies. While the relation-
ship between osteopenia and type 1 diabetes has been 
well defined [16], the effects of type 2 diabetes on bone 
metabolism have not yet been clearly identified. In this 
study, our aim was to investigate whether there was 
a difference between postmenopausal women with 
and without low BMD in terms of adipocytokines such 
as leptin, adiponectin and insulin resistance; and to 
identify the differences between the same parameters 
according to the level of BMD in type 2 diabetic patients.
Material and methods
The study patients were postmenopausal women 
who were referred to our hospital for measurement 
of BMD. Postmenopausal was defined as not having 
had a menstrual period for at least one year [17]. We 
excluded patients who had rheumatic diseases, chronic 
hepatitis and renal diseases, endocrinological disorders 
such as pituitary and thyroid diseases, patients over 
the age of 65 years and patients receiving glucocor-
ticoids, calcium, vitamin D, bisphosphonates and 
hormone replacement therapy. Postmenopausal type 
2 diabetic (n = 19) and nondiabetic patients (n = 19) 
with spine and/or hip BMD T score lower than –2 were 
included in the study, and postmenopausal type 2 dia-
betic (n = 20) and nondiabetic women (n = 18) with 
normal BMD (T score > –1) were selected as control 
groups. All diabetic women were diagnosed as diabetes 
mellitus after the age of 35. Women were matched by 
age and length of the postmenopausal period. There 
was no statistically significant difference between 
diabetics and nondiabetics according to age or length 
of postmenopausal period. 
The diabetic patients’ group included five patients 
who used insulin, 29 patients taking oral anti-diabetic 
drugs, two patients who used oral anti-diabetic and 
insulin together, two patients who did not take any 
medication, but rather controlled their blood glucose by 
diet, and one patient who had recently been diagnosed 
as diabetic. Patients’ body weight, height and waist 
circumference were measured and then BMI was cal-
culated according to the formula. Blood sampling was 
performed after an overnight fast. The blood samples 
were centrifuged for four minutes at 3,500 rpm and 
serum samples were obtained. Biochemical markers 
(plasma glucose, creatinine, lipid profiles, alkaline phos-
phatase, calcium, phosphorus) were measured with 
a biochemistry autoanalyser (Aeroset®, Abbott, Abbott 
Park, IL, USA) by standard biochemical methods. Os-
teocalcin levels were measured using the electrochemi-
luminescent method (Elecsys 1010®, Roche, Weinheim, 
Germany). Deoxy-pyridinoline levels were calculated 
using the chemiluminescent immunometric assay 
method (Immulite 2000®, DPC, Los Angeles, CA,USA) in 
24-hour urine test. Frozen plasma samples were thawed 
at room temperature and then serum adiponectin levels 
were identified by means of a commercial kit (Human 
Adiponectin ELISA KIT®, Linco Research, St Charles, 
MO, USA) and ELx 808 IU Ultra Microplate instru-
ment (Bio-Tek Instruments Inc, Winooski, VT, USA). 
Serum leptin levels were assessed using a commercial 
kit (Biosource LEPTIN EASIA KIT®, Nivelles Belgium) 
and ELx 808 IU Ultra Microplate instrument (Bio-Tek 
Instruments Inc). Serum insulin levels were assessed 
by means of a commercial kit (Biosource INS- EASIA 
KIT® Nivelles Belgium) and ELx 808 IU Ultra Microplate 
instrument (Bio-Tek Instruments Inc.).
Insulin resistance was calculated by the HOMA-IR 
method, which is frequently used in practice. HOMA-IR 
score was calculated by the following formula defined 
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by Matthews [18]. HOMA-IR = [fasting serum insulin 
(μIU/mL) x serum glucose (mmol/dL)]/22.5. According 
to this method, a high HOMA-IR score indicates low 
insulin sensitivity. This method is less complicated, 
cheaper and more practical in detecting insulin sensitiv-
ity compared to the glucose clamp technique. 
BMD measurement was performed using the DEXA 
method (Norland XR-46®, Norland Corp, Fort Atkinson, 
WI, USA) on lumbar vertebrae and proximal femur ar-
eas. L2-L4 vertebrae, femur neck, femur trochanter and 
Ward’s triangle bone mineral densities were assessed 
in gram/cm²; lumbar vertebrae and femur neck T and 
Z scores were defined. Fat mass, lean mass and total fat 
percentages were assessed by means of full body scan 
performed by the same instrument. Lean mass and fat 
mass were calculated in grams.
Statistical analysis 
Computer software was used for the statistical analysis 
(SPSS ver. 13, Chicago, IL, USA). Quantitative data 
was expressed in average ± standard deviation. In the 
analysis of demographic data of the patients one-way 
analysis of variance (one way ANOVA) was used. 
Pearson’s correlation coefficient was used in testing 
the relation between the parameters. Kruskal-Wallis 
test was used in testing whether there was a statisti-
cally significant difference between the groups or not. 
Mann-Whitney U test was used to test the significance 
of the difference between two groups. In the compari-
son of diabetic and non-diabetic patients and patients 
with and without osteoporosis, student-t test was 
employed. Statistical significance was accepted when 
p < 0.05.
Results
Demographic characteristics of the patients analysed 
under four groups are set out in Table I. The average 
age of the patients in group 4 was significantly lower 
than the average age of those in group 1. Similarly, 
menopause period was found to be significantly shorter 
in group 4 compared to group 1 and group 3.
Fasting blood glucose and HbA1c levels of the diabetic 
group (groups 1 and 2) were detected to be signifi-
cantly high in comparison with the non-diabetic group 
(groups 3 and 4). Triglyceride levels of the patients in 
group 1 were found to be higher compared to all other 
groups. No significant difference was defined between 
the groups in terms of biochemical parameters, insulin, 
leptin, or adinopectin levels, except for insulin resistance 
(Table II). Spine and hip BMD values of each group are 
shown in Table III.
Discussion
In this study, our aim was to detect whether there 
was a relationship between leptin, adiponectin, insulin 
resistance, and BMD in postmenopausal women with 
and without osteoporosis and to define the differences 
in the same parameters of type 2 diabetic women with 
and without osteoporosis. At the end of the study, 
we could not identify any correlation between leptin, 
adiponectin and insulin resistance, and bone mass in 
diabetic and nondiabetic patients with and without 
low BMD.
In recent clinical studies, it has been reported that 
adult patients with congenital leptin deficiency have 
low BMD despite their increased fat mass [19]. A child 
with congenital leptin deficiency responded well to re-
combinant leptin injection, and an increase in the BMD 
alongside a decrease in the fat mass was observed [20]. 
Takeda et al. explained that the sympathetic nervous 
system was the mediator to the intracerebroventricular 
effects of leptin. Osteoblasts express  adrenergic recep-
tor and  adrenergic agonist application inhibits bone 
formation which leads to a decrease in the trabecular 
bone mass [21]. Recent data indicates that elevated 
Table I. Demographic characteristics of the groups
Tabela I. Charakterystyka demograficzna badanych 
Group 1 
DM & low BMD 
(n = 19)
Group 2 
DM & normal BMD 
(n = 20)
Group 3 
NonDM & low BMD 
(n = 19)
Group 4 
NonDM & normal BMD 
(n = 18)
Age (years) 58.00 ± 4.35 * 55.26 ± 4.38 54.89 ± 4.86 52.83 ± 3.60
Postmenopausal period (years) 10.16 ± 6.71* 7.42 ± 5.92 8.68 ± 5.09 * 4.76 ± 3.99
Body weight [kg] 84.21 ± 14.30 78.05 ± 15.48 78.15 ± 17.01 79.72 ± 15.04
BMI [kg/m2] 36.17±6.41 33.35±6.06 33.76±7.60 34.09±6.48
Waist circumference [cm] 106.36 ± 27.74 102.95 ± 13.39 103.36 ± 14.65 104.94 ± 13.44
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sympathetic activity level increases bone resorption 
[22]. On the contrary, subcutaneous infusion of leptin to 
ob/ob mouse led to an increase in bone mineral content 
and decreased the adipose tissue quantity in the bone 
marrow [23]. These findings indicated that there was 
a positive correlation between endogenous leptin levels 
and BMD. The results of these studies suggest that the 
effect mechanism of leptin in circulation on the bone 
might be independent from the fat mass [9]. 
Goulding et al. found significant correlation be-
tween serum leptin level and deoxy-pyridinoline and 
hydroxy-pyridinoline, bone resorption biomarkers, and 
osteocalcin in postmenopausal women [8]. On the other 
hand, Yamauchi et al. did not detect any significant 
correlation between plasma leptin levels and urinary 
deoxy-pyridinoline and osteocalcin in postmenopausal 
women [9].
In our study, we did not find any significant rela-
tion between serum leptin levels and bone formation 
and resorption biomarkers such as osteocalcin, and 
deoxy-pyridinoline. As a result, plasma leptin levels 
do not have a correlation with the biochemical mar-
kers of either osteoclastic or osteoblastic activity, which 
suggests that leptin does not play a direct role in bone 
metabolism [8]. Kontogianni et al. defined a negative 
correlation between leptin and L2–L4 vertebrae BMD 
in perimenopausal women [4]. We found a negative 
correlation between femur Ward’s triangle and leptin in 
Table II. Biochemical evaluation and insulin, insulin resistance, leptin, and adiponectin values of the groups
Tabela II. Parametry biochemiczne, insulinooporność oraz stężenia insuliny , leptyny i adiponektyny w poszczególnych grupach
Group 1 
DM & low BMD 
(n = 19)
Group 2 
DM & normal BMD 
(n = 20)
Group 3 
NonDM & low BMD 
(n = 19)
Group 4 
NonDM & normal BMD 
(n = 18)
Fasting blood glucose [mg/dL] 154.52 ± 59.78* 171.40 ± 67.49* 96.63 ± 8.10 98.05 ± 7.80
HbA1c (%) 7.17 ± 1.76* 7.46 ± 1.40* 5.24 ± 0.38 5.46 ± 0.64
Triglyceride [mg/dL] 201.94 ± 74.89** 127.80 ±66.92 143.00 ± 98.27 141.05 ± 68.93
Cholesterol [mg/dL] 199.36 ± 62.63 184.60 ± 66.92 143.00 ± 98.27 141.05 ± 68.93
HDL-cholesterol [mg/dL] 55.21 ± 14.64 53.70 ± 13.74 55.16 ± 15.91 60.11 ± 19.39
Calcium [mg/dL] 9.69 ± 0.29 9.68 ± 0.52 9.74 ± 0.38 9.87 ± 0.37
Phosphorus [mg/dL] 3.97 ± 0.68 3.82 ± 0.45 3.65 ± 0.76 3.80 ± 0.49
Alkaline phosphatase [U/L] 117.68 ± 66.79 107.85 ±64.29 110.01 ± 58.33 106.16 ± 46.95
Osteocalcin [ng/mL] 20.20 ± 14.61* 18.50 ± 6.52* 29.66 ± 8.47 26.36 ± 8.97
Deoxypyridinoline 
[nmol/mg creatynine] 8.57 ± 10.38 6.04 ± 1.91 7.11 ± 2.26 6.91 ± 2.43
Insulin [μU/mL] 18.94 ± 11.52 17.54 ± 12.70 17.48 ± 10.51 14.24 ± 5.35
Insulin resistance (%) 6.97 ± 4.09* 8.34 ± 9.44 * 4.15 ± 2.47 3.49 ± 1.47
Leptin [ng/mL] 10.09 ± 6.77 9.12 ± 6.31 10.82 ± 7.55 10.34 ± 7.27
Adiponectin [μg/mL] 7.31 ± 6.45 6.44 ± 3.16 7.68 ± 3.30 7.58 ± 3.23
*compared to groups 3 and 4, p < 0.05; **compared to groups 2, 3 and 4, p < 0.05
Table III. Bone mineral measurements of the groups
Tabela III. Gęstość mineralna kości w poszczególnych grupach
Group 1 
DM & low BMD 
(n = 19)
Group 2 
DM & normal BMD 
(n = 20)
Group 3 
NonDM & low BMD 
(n = 19)
Group 4 
NonDM & normal BMD 
(n = 18)
Lumbar spine BMD [g/cm2] 0.82 ± 0.76* 1.13 ± 0.16 0.81 ± 0.11* 1.10 ± 0.77
Femoral neck BMD [g/cm2] 0.68 ± 0.12*  0.91 ± 0.97 0.71 ± 0.85* 0.89 ± 0.78
Trochanter BMD [g/cm2] 0.61 ± 0.93* 0.74 ± 0.93 0.59 ± 0.56* 0.76 ± 0.10
Wards triangle BMD [g/cm2] 0.47 ± 0.12* 0.70 ± 0.11 0.46 ± 0.77* 0.69 ± 0.80
*compared to groups 2 and 4, p < 0.05
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our study, while we could not report such an association 
for L2–L4 vertebrae BMD. Femur Ward’s triangle is rich 
in trabecular bone, just like the vertebrae. Degenera-
tive changes in vertebrae bones, which are associated 
with obesity, may lead to false high levels of vertebrae 
BMD. Isparta is an endemic region for fluorosis and 
fluorosis-induced osteosclerosis. So women may have 
higher BMD than normal [24, 25]. This could be the 
reason why we could not detect a negative relation 
between leptin and vertebra BMD in this study.
Serum leptin levels are higher in obese patients. Never-
theless, the relation between leptin and obesity asso-
ciated diabetes is not very well known [26]. Kontogianni 
et al. found a significant positive correlation between 
leptin levels and BMI, fat percentage, free fat mass and 
lean body mass in their study [4]. 
Adiponectin levels are low in obese, hyperinsulinae-
mic and type 2 diabetic patients and adiponectin levels 
also increase with age [27]. In our study, adiponectin 
levels were lower in type 2 diabetic patients compared 
to the non-diabetics, however the difference was not sta-
tistically significant. Although there wasn’t a statistically 
significant difference in age between type 2 diabetic 
and non diabetic groups when considered as a whole 
group, type 2 diabetic patients’ groups in our study had 
a higher average age than the non-diabetic groups and 
the smaller number of patients in these groups might 
be the reason why we did not find any significant dif-
ference between adiponectin levels. Although there is 
a common stem cell in the bone marrow for adipocytes 
and osteoblasts, and in spite of the information available 
on the synthesis of various adipocytokines in the osteob-
lasts, the relationship between leptin, adiponectin and 
BMD is controversial. We did not find any difference 
between the postmenopausal female patient groups 
with and without osteoporosis in terms of leptin or 
adiponectin levels. The low number of patients might 
have prevented any significant correlation. However, 
there are different conclusions in the literature as well. 
When we categorised the diabetic patients into two 
groups as those with and without osteoporosis, we 
also did not find a difference in leptin or adiponectin 
levels. The interesting correlation indicating the interac-
tion between adipocytes and bone metabolism should 
be clarified in further studies.
Adipocytes express adiponectin abundantly and 
specifically, and it has been reported that adiponectin 
receptors are detected in cells forming the bone [27]. 
Lenchik et al. analysed the possible relation between 
adiponectin levels and bone mass in their study 
which was conducted on 42 male and 38 female (86% 
of the women were postmenopausal) patients [28]. 
They defined an inverse proportion between the adi-
ponectin levels and BMD in all skeletal areas for all 
patients. Adiponectin has structural similarities with 
tumour necrosis factor-alpha (TNF-a) family mem-
bers, which have an important role in the regulation 
of osteoclastogenesis, and receptor activator nuclear 
factor kappa B ligand (RANKL) and osteoprotegerin. 
It has been demonstrated that adiponectin affects 
nuclear transcription factor kappa B (NFKB), which 
is a critical transcription factor for osteoclastogenesis 
[29, 30] and it is suggested to be one of the mecha-
nisms of adiponectin to affect the bone. Giving that 
recombinant adiponectin prevents adipogenesis at 
the preadipocytes which stem from bone marrow, this 
indicates that adiponectin has an impact on the bone 
marrow environment [31].
It is argued that insulin accelerates the synthesis of 
the bone matrix by stimulating the function of osteob-
lasts. Some researchers are of the opinion that insulin 
is necessary for normal bone mineralisation. There is 
also an argument that BMD increasing effect of obesity 
can be due to hyperinsulinaemia which is mostly seen 
with obesity, together [32]. Oner et al., in their study of 
30 non-obese and 30 obese postmenopausal women, 
suggested that higher BMD levels of the obese post-
menopausal women compared to the non-obese could 
be associated with insulin rather than weight stress and 
the effects of sex hormones [33]. Connor et al. [32] and 
Albala et al. [34] argue that insulin indirectly stimulates 
the function of osteoblasts as it increases the production 
of insulin like growth factor (IGF-1) in the liver and it 
is bound to the IGF-1 receptors since it is structurally 
similar to IGF-1. Then insulin could have a positive 
impact on BMD by increasing bone collagen synthesis 
and replication of preosteoblastic cells. 
In this study, we could not identify any correlation 
between serum insulin levels and femur and L2–L4 
vertebrae BMD.
The relationship between diabetes and BMD had 
been analysed in many studies. Although the relation 
between osteopenia and type 1 diabetes had been 
well defined before [16], the effects of type 2 diabetes 
on bone metabolism have yet to be clearly explained. 
There are studies referring to higher [35], similar [36] 
or lower [37] bone mass in type 2 diabetic patients 
compared to normal controls. Isaia et al. [38] measured 
lumbar vertebrae BMD of 49 postmenopausal diabetic 
and 28 non-diabetic women, and femoral (neck, inter-
trochanter, Ward’s) and total BMD of 65 diabetic and 
42 non-diabetic women. There was no significant dif-
ference between diabetic and non-diabetic groups for 
L2–L4 vertebrae BMD. At the femoral level, however, 
type 2 diabetic patients had higher BMD in areas other 
than the Ward’s triangle. They argued that higher BMD 
might be associated with the anabolic effect of hyper-
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different lumbar vertebrae and femur BMD values in the 
diabetic group can be explained by the fact that cortical 
bone might have been protected more [38]. Another 
reason for high BMD in diabetic patients is the negative 
effect of insulin on the sex hormone binding globulin. 
Low sex hormone binding globulin level coexists with 
high serum oestradiol levels [39]. In our study, we could 
not identify a significant difference between diabetic 
and non-diabetic patients in terms of femur and L2–L4 
vertebrae BMD. 
Cakatay et al. compared osteocalcin, total alkaline 
phosphatase, and urinary deoxy-pyridinoline levels 
in their study, which included 35 type 2 diabetic and 
35 non-diabetic patients. They identified significantly 
low osteocalcin levels in diabetic patients compared 
to the control group. No significant difference was 
reported for the other parameters [40]. 
In our study, when we compared the diabetic 
groups with the non-diabetics, we did not identify any 
significant difference between serum calcium, phos-
phorus, urine calcium, alkaline phosphatase, or urine 
deoxy-pyridinoline. On the other hand, we observed 
lower osteocalcin levels in diabetic patients.
Our study has some limitations. Firstly, the groups 
were not large enough or homogenous enough to make 
definite conclusions. Secondly, insulin or antidiabetic 
drugs such as glitazones that diabetic patients use were 
not estimated. Finally, vertebral fractures were excluded 
from consideration.
Conclusion
Although the majority of epidemiologic studies have 
highlighted the existence of the interaction between 
adiposity and bone, results of these studies have con-
trasting conclusions. In our cross-sectional study, we 
conclude that leptin adiponectin levels are not correla-
ted with BMD in either type 2 diabetics or nondiabeti-
cs. However, we believe that further research involving 
more participants and the investigation of local leptin 
and adiponectin levels in bony tissue are necessary 
to clarify the exact role of these adipocytokines in the 
bone metabolism. 
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